In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Roche licenses Antisoma's oncology compounds

Executive Summary

Roche licensed worldwide exclusive rights to develop, manufacture, and sell several Antisoma anticancer compounds. The five-year deal provides Roche with Phase III ovarian cancer candidate pemtumomab, Phase I compounds Therex, TheraFab, and DMXAA, and several early-stage oncology candidates.
Deal Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register